The U.S. Food and Drug Administration on Tuesday approved another drug that slows cognitive and functional decline in people ...
The clinic will provide two medications that can slow the progression of the disease in early stages: Leqembi and Kisunla.
The Food and Drug Administration (FDA) has approved Kisunla ™ (donanemab-azbt) for the treatment of Alzheimer disease.
3d
Zacks.com on MSNPharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPDEli Lilly LLY won a long-awaited FDA approval for its Alzheimer's disease (AD) drug, donanemab, to be sold under the brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results